Pooled Trial Data Link GLP-1 Therapies to Reduced Major Adverse Cardiovascular Events in Male Patients

Major Trials Associate GLP-1 Receptor Agonists With Lower Cardiovascular Event Rates in Men With Type 2 Diabetes

Large randomized trials have tied semaglutide and liraglutide to reductions in major adverse cardiovascular events among adults with type 2 diabetes at elevated risk. Male participants, who formed the majority in these studies, showed matching patterns in the subgroup results. The same agents drove marked weight loss in separate research on people with overweight or obesity. Taken together, the three trials supply an integrated view of cardiometabolic effects relevant to men who have both conditions.

What this means

The linked data tie GLP-1 receptor agonists to relative risk reductions in MACE of 13 to 26 percent. Those figures sit alongside weight loss that averaged close to 15 percent in obesity trials. Improvements in blood pressure, lipids and inflammatory markers often appear with such changes. Even so, the male findings come from subgroups within broader cohorts rather than studies built exclusively around men.

Key takeaways

• Semaglutide was associated with a hazard ratio of 0.74 for MACE in adults with type 2 diabetes at high cardiovascular risk. [1]
• Liraglutide showed a hazard ratio of 0.87 for the same composite endpoint. [2]
• Subgroup analyses found no significant treatment-by-sex interaction, and men made up the larger share of participants. [1][2]
• Once-weekly semaglutide produced mean weight loss of 14.9 percent at 68 weeks versus 2.4 percent with placebo. [3]
• All reported benefits occurred against a background of standard-of-care therapies. [1][2]

Three trials form the basis for these observations. The SUSTAIN-6 study tested semaglutide in patients with type 2 diabetes and high cardiovascular risk. It recorded a 26 percent relative drop in cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. [1]

The LEADER trial tested liraglutide in a comparable group. Its 13 percent risk reduction aligned with the semaglutide results. [2] Male subgroups in both studies tracked closely with the overall populations.

Weight loss supplies one possible mechanism. The STEP 1 trial enrolled adults with overweight or obesity, many of whom carried cardiometabolic diagnoses. Average body-weight reduction reached 14.9 percent with semaglutide. [3] Such shifts commonly coincide with favorable movements in blood pressure and lipid levels, though MACE was not the primary endpoint there.

Regulatory review of these and similar data led to label updates. The FDA added language on cardiovascular risk reduction for selected GLP-1 receptor agonists. Those changes rest on trials that enrolled mostly men.

Limitations

None of the trials were prospectively powered for male-only analysis. Subgroup findings should be considered exploratory. Follow-up duration is typically two to five years. Longer-term outcomes remain under study. Gastrointestinal side effects can limit real-world adherence. Background standard-of-care therapies were used, so incremental benefit depends on optimization of other treatments.

The evidence shows associations inside selected high-risk groups. It does not prove the same results would appear in lower-risk men, in those without diabetes, or over decades of use. Real-world adherence often falls short of trial conditions.

FAQ

What are the primary cardiovascular endpoints reduced by GLP-1 RAs in relevant trials?
The trials measured a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke.

Do subgroup analyses show differential effects or consistent benefits specifically in men?
Analyses reported consistent benefits with no significant treatment-by-sex interaction. Men comprised the majority of participants.

How does the degree of weight loss from GLP-1 RAs correlate with observed cardiovascular risk reduction?
Greater weight loss, averaging nearly 15 percent with semaglutide, tracks with improvements in blood pressure, lipids and inflammatory markers, yet the trials do not isolate how much of the MACE reduction stems from weight change alone.

What do regulatory bodies such as the FDA conclude regarding CV safety and benefit in this population?
The FDA incorporated cardiovascular risk reduction language into labeling for select GLP-1 receptor agonists after reviewing these outcomes.

Sources / References

1. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141

2. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. https://www.nejm.org/doi/full/10.1056/NEJMoa1603827

3. Once-Weekly Semaglutide in Adults with Overweight or Obesity. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183